This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.
4 Primary · 5 Secondary · Reporting Duration: Assessed every 8 weeks for the first year and every 12 weeks thereafter up to end of study at approximately 2 years
50 Total Participants · 2 Treatment Groups
Primary Treatment: Expansion Cohort · No Placebo Group · Phase 1
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: